Eli Lilly to Offer Breakthrough Migraine Drug for Free
*By Michael Teich*
[Twelve percent](https://migraineresearchfoundation.org/about-migraine/migraine-facts/) of the U.S. population may suffer from chronic migraines, but many Americans don't appreciate the impact, said president of Lilly Bio-Medicines Christi Shaw.
"These patients need to be treated seriously. This is a neurological disorder," Shaw said Friday in an interview on Cheddar.
Eli Lilly ($LLY) just received clearance from the FDA for its latest drug, and it could change the lives of the 39 million Americans suffering from migraines, according to Shaw.
The treatment, Emgality, is a monthly, self-administered injection that will help patients cut the frequency of their migraines in half, she said.
Shaw said that many Americans conflate headaches and migraines, and so they often dismiss their pain. They key difference is that the symptoms of a migraine disrupt one's ability to function optimally through the day. That doesn't happen with a more commonplace headache. And a stigma contributes to the glaring statistic that only about 10 percent of those suffering from migraines take prescription drugs for prevention, Shaw said.
Emgality comes with a serious price tag: $6,900 a year, or $575 a month. But Eli Lilly is offering commercially insured patients up to 12 months of the drug for free. It's among the latest efforts from the industry to offer consumers some relief from surging drug costs.
Competitors Amgen ($AMGN) and Teva ($TEVA) have already unveiled new migraine treatment drugs.
For full interview [click here](https://cheddar.com/videos/eli-lilly-gets-fda-approval-for-new-migraine-treatment).
New research shows that exposure to polyfluoroalkyl substances (PFAS), also known as "forever chemicals" can hamper growth and development in children by "altering hormonal and metabolic pathways."
The Centers for Disease Control and Prevention (CDC) on Monday warned that a deadly fungus called Candida auris (C. auris) is spreading at an "alarming rate" in the U.S. healthcare facilities.
Karuna Therapeutics' top-experimental schizophrenia drug significantly reduced symptoms in a late-stage trial but there were concerns that it could cause hypertension in patients.
One of television's most successful writers made a big donation to the Cedars Sinai Medical Center in Los Angeles to help underserved community members gain the skills to become health care professionals.
The UN Intergovernmental Panel on Climate Change (IPCC) has released a new report providing multiple options for how the world can survive and adapt to climate change.
California Gov. Gavin Newsom over the weekend announced that the state has secured a contract with CIVCA to make $30 insulin available to all who need it. He also announced that the state will start manufacturing Naloxone, an emergency medication used to rapidly reverse the effects of an opioid overdose.
The global bottled water industry is booming, and it's coming at a steep environmental cost, according to the United Nations University Institute for Water, Environment and Health.
